Navigation Links
Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. reported today that data from Study 16 and Study 17 of the Phase 2B clinical trial program evaluating bremelanotide in men with erectile dysfunction (ED) were presented yesterday at the American Urological Association (AUA) Annual Meeting (AUA 2007) held in Anaheim, CA. New positive data presented showed that bremelanotide improved both self-esteem and sexual relationship in men with erectile dysfunction (ED). Other positive top line data from the Phase 2B clinical trial program were reported by the companies in November 2006 and at the 9th European Society for Sexual Medicine (ESSM) Congress in Vienna in December 2006.

In order to better understand the effects that bremelanotide may have on improving quality of life and self-esteem, patients in Study 16 were administered the SEAR (Self-Esteem and Relationship), a validated psychological instrument with two major domains: sexual relationship and confidence. The SEAR data were presented at AUA 2007 by Stanley E. Althof, PhD, Professor of Psychology, Case Western Reserve School of Medicine in a session entitled Improvement in Sexual Relationship, Satisfaction, Confidence and Self-Esteem in Erectile Dysfunction Patients Treated with Bremelanotide.

Dr. Althof commented, "Our analysis has shown that treatment with bremelanotide improved both the Self-Esteem and Sexual Relationship domains of the SEAR in non-diabetic ED patients and this was strongly correlated with improvements in erectile function. These results indicate that bremelanotide improves sexual confidence and has the potential to be an important treatment option for patients with ED."

"An increasing focus and attention on the utility of therapy in restoring quality of life and improvements to interpersonal relationships continues to evolve and will driv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...
(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
(Date:11/24/2009)...type device to be coupled with Stem Cell Therapy. ...ovember 24, 2009 -- Entest Biomedical, Inc. (OTC...ons with a manufacturer of lasers regarding the de...l be owned by Entest and used in conjunction with ...ped by Entest. These therapies are aimed at increa...
(Date:11/24/2009)...l Tips to Get a Leg Up From the American Podiatric...thesda, Md. (Vocus) November 24, 2009 -- The avera...dash;but that number dramatically increases during...s alike continue making their holiday travel plans...ar the brunt of aches and pains while on the road....
(Date:11/24/2009)...wire/--MinuteClinic,thepioneerandlargestproviderof...tsfirstretailhealthcarecenterinWashington,D.C.insi...pensevendaysaweekandwillservepatientsinNortheastne...anPark,AtlasDistrict,IvyCityandtheGallaudetUnivers...ore-basedclinic,weareexpandingaccesstohigh-quality...
(Date:11/24/2009)...wswire-FirstCall/--AflacIncorporated(NYSE: AFL )an...dtheexchangeoftwoofitsinvestmentsecuritiesownedbyA...November3,2009,andtheexchangesareexpectedtosettleo...flacwillhaveexchangeditsinvestmentinLloydsTSBBankp...arvalueof$222millionatSeptember30,2009)intoyen-den...
(Date:11/24/2009)...redators, but few fear cyberbullying, survey finds...- More than four in five parents say their childre...at the same time almost two-thirds are worried abo...The findings, released online Nov. 19 by the C.S. ...,s Health, show that parents have a variety of con...
Breaking Medicine News(10 mins):Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3Health News:MinuteClinic Opens First Retail Clinic in Washington, D.C. at CVS/pharmacy Store in Northeast 2Health News:MinuteClinic Opens First Retail Clinic in Washington, D.C. at CVS/pharmacy Store in Northeast 3Health News:Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio 2Health News:Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio 3Health News:Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio 4Health News:Parents Worry About Their Kids' Safety on the Internet 2
... gets tough, the tough get fitter, and healthier. ...is still going strong despite these challenging ec...owth strategy not only for this year but for many ...ak. , , Known for its innovative results-oriente...
...ry in Miami today convicted two physicians and two...ion Medicare fraud scheme, Acting Assistant Attorn... and U.S. Attorney R. Alexander Acosta of the Sout...65; Eda Marietta Milanes, 43; and Jorge Luis Pache...
...amp; Sullivan will present the 2009 Excellence in... Market to Epinex for developing the G1A(TM) Rapi...livan is an internationally renowned market resear...llence in Medical Technologies & Life Sciences...
...ng event was announced today by the American Red C...ter Los Angeles Red Cross is hosting a lunch recep...ency Operations Center (EOC), which is ready to be...ge will run throughout the event. , , Who: More...
...ty revenue triples and GCC sales start , , QUEBEC...e Inc. (TSX: CUR), a life sciences company commerc...livering lab services, announced a net loss of $3,...eflect budgeted sales and marketing initiatives to...
...argest water efficiency conference Oct. 7-9 in Las...t of its ongoing commitment to encourage efficient... Association (AWWA), the authoritative resource o...ed last year by the Southern Nevada Water Authorit...
Other Medicine News:Health News:Equinox Fitness Clubs Grows With The Flow 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4Health News:Frost and Sullivan Picks Epinex for Diabetes Research Award 2Health News:State-of-the-Art Preparedness: L.A. Red Cross Opens Advanced Emergency Operations Center 2Health News:DiagnoCure announces first quarter 2009 results 2Health News:DiagnoCure announces first quarter 2009 results 3Health News:DiagnoCure announces first quarter 2009 results 4Health News:DiagnoCure announces first quarter 2009 results 5Health News:DiagnoCure announces first quarter 2009 results 6Health News:AWWA partners with WaterSmart Innovations conference 2
Schepens Depressor 8.0mm Wide Tip Thimble Size 12
Yavitz Flap Cover
Chayett Drainage Ring
Weck-Cel Points
Medicine Products: